Science Hub
Welcome to Novo Nordisk Science Hub
The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.
The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.
Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.
By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.
Dr Matthew A. Cavender, MD, MPH is an Assistant Professor and the
Director of the Cardiology Clinical Outcomes Group and Co-Director of
Cardiovascular Clinical Trials at the University of North Carolina in
Chapel Hill, NC.
He is clinically active as an interventional cardiologist and specializes in transcatheter therapies for patients with advanced coronary artery disease, peripheral vascular disease, and valvular heart disease. He has extensive experience in clinical research studying the clinical effectiveness of clinical interventions, devices, and pharmacotherapies. His research efforts are focused on the effectiveness of existing treatment strategies and therapies for patients with cardiovascular disease, the impact of diabetes on cardiovascular events among patients with coronary artery disease, and pharmacologic and interventional strategies to improve outcomes in patients with diabetes and atherosclerosis.
Dr Cavender is a Fellow of the American College of Cardiology and a member of several medical societies and organizations, including the American Heart Association Council of Clinical Cardiology, and the Society for Cardiovascular Angiography and Interventions.
Adie Viljoen
MBChB FCP(SA) MMed FRCPath MBA, Lister Hospital & Cambridge Universities NHS Trust, UK
Dr Adie Viljoen is a clinical specialist and works as a Consultant
Chemical Pathologist and Metabolic Physician in Hertfordshire, UK,
having trained in South Africa where he received his medical and
specialty medicine qualifications. He conducts clinics in diabetes,
cardiovascular risk prevention, lipid and metabolic disorders and his
interests include type 2 diabetes and diabetic dyslipidaemia,
diabetes.
He is a Senior Lecturer in Medicine at the Bedfordshire and Hertfordshire Postgraduate Medical, and a Member of the Institute for Diabetes in Older People (IDOP). He is the UK Chief Investigator and Principal Site investigator for several international phase 2 and 3 research trials in diabetes, obesity and lipids including studies such as EXAMINE, ORIGIN, 4T, CRESCENDO. He is a member of the Scientific Research Committee of HEART UK and the UK cholesterol charity.
Read full bio
David Strain
MD, University of Exeter Medical School, UK
Dr David Strain is a Senior Clinical Lecturer at the University of
Exeter Medical School in the UK. He is an honorary consultant in
medicine for the older adult, Head of the academic department for
healthcare for older adults, and the co-chair of the British Medical
Association’s medical academic staff committee. Clinically, he runs a
community diabetes service for the older adult, works as an in-patient
stroke consultant, and participates in the chronic fatigue
service.
His main research focus is the health of older adults with diabetes and ensuring the right patient gets the right treatment. This includes research across the spectrum from mechanistic studies in the biologically young to pragmatic trials in the frail elderly population. He was the lead author on the UK guidance for the assessment and management of older adults with diabetes and frailty, which has recently led to a change in the NICE guidance and primary care contract.
He has performed the only study to date demonstrating the feasibility of individualizing targets for older adults across Europe and since March 2020, he has been heavily involved in the COVID-19 response team.
Read full bio
Juris Jendrik Meier
Professor, Augusta Clinic, Germany
Professor Meier is the chief physician at the Department of Internal
Medicine, Gastroenterology, Hepatology and Diabetology at Augusta
Clinic. His research centres on physiological actions and therapeutic
applications of incretin hormones, mechanisms of beta-cell death in
patients with diabetes, kinetics of beta-cell turnover in humans,
diabetes secondary to chronic pancreatitis, and the regulation of
insulin secretion in vivo.
Prof. Meier has received several honours for his research, and he serves as a reviewer for several international journals. He is also a member of numerous professional societies and committees including the German Diabetes Association (DDG), European Association for the Study of Diabetes (EASD), and the American Diabetes Association (ADA).
Read full bio
Peter Rossing
MD, DMSc, Steno Diabetes Center, Denmark
Professor Peter Rossing is a clinician researcher devoted to
complications in diabetes with a focus on renal and cardiovascular
complications. He holds a specialist degree in internal medicine and
endocrinology and is Chief physician and manager of the Steno Diabetes
Center research team dedicated to the research of micro-and
macrovascular complications of diabetes.
Professor Rossing has investigated key features of the
pathophysiology of the diabetic kidney at different stages in
epidemiological studies. He has identified several markers for
development of diabetic nephropathy, making it possible to predict the
individual risk. He has been involved in several intervention studies
in patients with overt diabetic nephropathy aiming at improving the prognosis.
Professor Rossing is a coordinator of the EU FP7
project PRIORITY, which aims to test if urinary proteomics can be used
to stratify prevention of renal complications in type 2 diabetes, and
the Novo Nordisk Foundation grant PROTON, which aims at personalising
prevention of diabetic nephropathy.
Read full bio
Tina Vilsbøll
MD DMSc, Center for Diabetes Research at Gentofte Hospital, University of Copenhagen, Denmark
Professor Vilsbøll has been involved in diabetes research since 1997, and in 2004 she established the Center for Diabetes Research at Gentofte Hospital, University of Copenhagen, Denmark now part of Steno. Her research is focused on the pathophysiology of obesity, prediabetes, type 2 diabetes, regulation of appetite and food intake, and the utilisation of incretins as therapeutics. Integration of the gut in the understanding of human glucose metabolism has become a major focus in her lab over recent years. Professor Vilsbøll is an experienced teacher and supervises several PhD and medical students conducting diabetes research. She is a frequently invited speaker at international meetings. In addition to her teaching and research posts, Professor Vilsbøll is a member of numerous professional societies and committees, and referees for several international journals.
Read full bio